Global, regional, and national burdens of MDR-TB attributable to smoking from 1990 to 2021 with a prediction from 2022 to 2050

Objective: The aim was to offer a comprehensive epidemiological assessment of the global prevalence and the smoking-related Multidrug-resistant tuberculosis (MDR-TB) disease burden from 1990 to 2021 and to forecast the trends in smoking burden over three decades. Methods: We compared the burden of smoking-related MDR-TB and temporal trends by gender, age, socio-demographic index (SDI), region, and country. Forecasting analyses of the changing trend in the burden of smoking-related MDR-TB up to 2050 was conducted based on the ARIMA model and ES models. Results: The global age-standardized rate (ASR) of smoking-related MDR-TB increased from 1990 to 2021, highlighting a significant disease burden. In 2021, the cumulative Disability adjusted life years (DALYs) attributed to MDR-TB tallied up to 239,707 cases, with Lesotho, Uzbekistan, Kyrgyzstan, bearing the brunt. The likelihood of developing MDR-TB rose as individuals advanced in years, manifesting most acutely among men aged 35-39 in lower SDI and Low-middle SDI regions. Predictive analysis suggests that by 2050, deaths and DALYs of smoking-related MDR-TB, as well as their corresponding ASR, will continue to decrease. Conclusion: The burden of MDR-TB worldwide, adjusted for age, and related to smoking, has shown a decline from 1990 to 2021. However, regional disparities have been identified, with some areas experiencing an increase in this burden. These regions with a higher burden emphasize the necessity for the implementation of strong tobacco control measures

Burden of disease · Disease burden · Public health · Tobacco control · Immune responses and vaccinations · Pediatric health and respiratory diseases · Tuberculosis Research and Epidemiology · Epidemiology

• Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019

  Open Access•Marissa B Reitsma, Parkes J Kendrick et al.•The Lancet•2021

  Incluir item

• Guidelines for Accurate and Transparent Health Estimates Reporting

  Open Access•G A Stevens, Leontine Alkema et al.•The Lancet•2016

  Incluir item

• Global Effects of Smoking, of Quitting, and of Taxing Tobacco

  Prabhat Jha, Richard Peto•New England Journal of Medicine•2014

  Incluir item

• Global burden of 87 risk factors in 204 countries and territories, 1990–2019

  Open Access•Christopher J L Murray, Aleksandr Y Aravkin et al.•The Lancet•2020

  Incluir item

• Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019

  Open Access•Theo Vos, Stephen S Lim et al.•The Lancet•2020

  Incluir item

• Tracking multidrug resistant tuberculosis

  Open Access•Hui-Wen Song, Jianhua Tian et al.•Frontiers in Public Health•2024

  Incluir item

• A Media Analysis of the Covid-19 Tobacco Sales Ban in South Africa

  Open Access•Chengetai Dare, Nicole Vellios et al.•International Journal of…•2023

  Incluir item

• Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019

  Open Access•Sharofiddin Yuldashev, Sharofiddin Sharipov et al.•International Journal of…•2021

  Incluir item

• Covid-19 and a temporary ban on tobacco sales in South Africa

  Open Access•Yussuf Saloojee, Angela Mathee•Tobacco Control•2021

  Incluir item

• The temporary ban on tobacco sales in South Africa

  Open Access•Samantha Filby, Kirsten Van Der Zee et al.•Tobacco Control•2021

  Incluir item